Nasdaq

Design Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025

Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...
Business Wire

Trefoil Therapeutics’ Lead Investigational Candidate TTHX1114 Improves Rate of Visual Recovery after Descemet Stripping Only (DSO) in Phase 2 STORM Data Presented at ASCRS ...

SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics, a clinical-stage biotechnology company focused on developing novel new therapeutic agents to treat corneal diseases, today announced that TTHX1114 was ...
Seeking Alpha

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today ...
Yahoo

Focus on Eyes: Cloudy eyes, discomfort could be symptoms of Fuchs' dystrophy

Add Yahoo as a preferred source to see more of our stories on Google. In 1910, Professor Ernst Fuchs, an Austrian ophthalmologist, published an article describing 13 patients with Fuchs’ dystrophy, a ...
Seeking Alpha

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today ...
News Medical

Study uncovers mechanisms behind Fuchs Endothelial Corneal Dystrophy

Important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers. The study ...